|
Canada-0-LaboratoriesTesting कंपनी निर्देशिकाएँ
|
कंपनी समाचार :
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body . . . - Cell Press
Talukdar et al describe the effects of a long-acting FGF21 analog, PF-05231023, in obese monkeys and obese overweight humans with type 2 diabetes In both humans and monkeys, PF-05231023 decreased body weight, improved the circulating lipid profile and increased adiponectin levels In humans, PF-05231023 treatment resulted in multiple changes in markers of bone turnover
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and . . .
PF-05231023 treatment led to dose-dependent changes in multiple markers of bone formation and resorption and elevated insulin-like growth factor 1 The favorable effects of PF-05231023 on body weight support further evaluation of this molecule for the treatment of obesity
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and . . .
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and . . .
Journal of bone and mineral metabolism, 2016 Fibroblast growth factor (FGF)-21 is a potent endocrine factor that improves insulin resistance and obesity-associated metabolic disorders However, concomitant activation of peroxisome proliferator-activated receptor-γ by FGF-21 makes bone susceptible to osteopenia and fragility fracture Since an increase in body weight often induced adaptive
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body . . . - EurekaMag
PF-05231023 treatment led to dose-dependent changes in multiple markers of bone formation and resorption and elevated insulin-like growth factor 1 The favorable effects of PF-05231023 on body weight support further evaluation of this molecule for the treatment of obesity
- Once-weekly administration of a long-acting fibroblast growth factor 21 . . .
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates
- Metabolic Messengers: FGF21 - Nature Metabolism
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with
- PF-5231023 - Drug Targets, Indications, Patents - Synapse
FGF21 has a short half-life (0 5-2 h) and crosses the blood-brain barrier Therefore, we set out to identify molecular mechanisms for both the naïve form of FGF21 and a long-acting FGF21 molecule (PF-05231023) in induced pluripotent stem cell (iPSC)-derived forebrain neurons
- Once‐weekly administration of a long‐acting fibroblast growth factor 21 . . .
Conclusions Once‐weekly PF‐05231023 lowered triglycerides markedly in the absence of weight loss, with modest changes in markers of bone homeostasis This is the first report showing increases in BP and pulse rate in humans and rats after pharmacological administration of a long‐acting FGF21 molecule
- PF-05231023 | CAS NO. :1037589-69-7 | GlpBio
PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog [1] PF-05231023 binds to the FGF21 receptor complex (FGFR1c and Klb), activating downstream signaling pathways that regulate energy metabolism, glucose homeostasis, and lipid metabolism [2-3]
|
|